Cell Line Development Services Global Market – Forecast to 2025

Publishing Date : August, 2017
Report Code : HCBT0114
Price:
Single license $3,600
Site license $5,400
Global license $7,200


Cell lines are one the major tools used in research for studying the normal physiology and biochemistry of cells, the effects of drugs and toxic compounds on the cells, drug screening and development and large scale manufacturing of biological compounds. Cell culture is the process by which cells are grown under controlled conditions derived from microbial or animal cells. Cell lines are subculture of primary culture also known as sub-clone. Cell lines derived from primary cultures have a limited life span, after subsequent cultures, cells with the highest growth capacity dominate which are selected for further cell development. Primary cells are cells that are cultured directly from a subject and have a limited lifespan. An immortalized cell line can proliferate indefinitely either through random mutation or deliberate modification which are useful especially for production of therapeutics.

The cell line development service market is expected to grow at double digit CAGR to reach $1,214.7 million by 2025. Increasing demand for biologics and biosimilars, growing incidence rate of oncology and immunological disorder and growth in research activities related to the diseases are driving the market. Technological improvements in development, manufacturing, screening technologies and assays are giving immense growth opportunity for the market. However, complexities in development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market. Furthermore, stringent and complex regulations and high cost and technical requirement to adhere with accreditations such as GMP are posing threat to the industry.

Cell lines are essential for a wide range of applications including gene function studies, drug discovery assays, the production of biotherapeutics and diagnostics. The application for cell lines includes research, bioproduction and diagnostics. Among research, cell lines are used for studying disease, screening, cell-based assays are used during discovery phase and preclinical development. Cell lines are used to produce a wide range of biotherapeutics including vaccine, recombinant proteins that include peptides, cytokines, hormones and clotting factors, enzymes and monoclonal antibodies.

 

Some of the major companies in the cell line development market include Lonza (Switzerland),Fujifilm Diosynth (Japan) , Merck KGaA (Germany), Selexis S.A. (Switzerland), Rentschler Biotech (Germany), Horizon Discovery (U.K.), Sartoris Stedim (France), Wuxi Apptec (China), Boehringer Ingelheim (Germany) and Cook Pharmica (U.S.).

Some of the other players are Patheon (The Netherlands), Syngene (India), Crown Bioscience (U.S.), Evotec (Germany), Catalent (U.S.), Lake Pharma (U.S.), TCG Lifescience (India), Cobra Biologics (U.K.), Eurofins (Luxembourg ), Abzena (U.K.), JHL Biotech (Taiwan), Charles River Laboratories (U.S.), Genscript (China), Mabplex (U.S.),  Trenzyme (Germany), JSR Life Sciences (U.S.), Atum (U.S.), ATCC (U.S.).

The cell line development services global market was estimated region wise, by type of cell lines expression systems, by cell types and by application. This report also contains cost analysis for various cell line development services. Key developments such as collaborations, acquisitions, new launches, partnerships and expansions were reported and analyzed.

  • In depth assessment of all segments and sub segments of cell line development services global market
  • Regional analysis of cell line development services global market
  • Market dynamics for cell line development services global market
  • Cost analysis of different cell line development services and cell based assays
  • Cell line type used in approved biologics (2012-2016) and analysis based on type of modality
  • Comparison matrix of various key players with cell line development capabilities
  • 1     EXECUTIVE SUMMARY
  • 2     MARKET DYNAMICS
    • 2.1     MARKET DYNAMICS
      • 2.1.1     DRIVERS AND OPPORTUNITIES
        • 2.1.1.1     GROWING INCIDENCE RATES OF ONCOLOGY AND IMMUNOLOGICAL DISORDERS AND INCREASING R&D ACTIVITIES RELATED TO THE DISEASES.
        • 2.1.1.2     INCREASING DEMAND FOR BIOLOGICS AND BIOSIMILARS
        • 2.1.1.3     ADVANCED TECHNOLOGIES FOR SCREENING, CELL LINE ENGINEERING AND BIOPROCESSING
        • 2.1.1.4     INCREASING NUMBER OF CROS IN APAC REGIONS
      • 2.1.2     RESTRAINTS AND THREATS
        • 2.1.2.1     COMPLEXITIES IN DEVELOPMENT OF STABLE CELL LINES
        • 2.1.2.2     HIGH RISK OF CONTAMINATION DUE TO COMPLEX PURIFICATION METHOD
        • 2.1.2.3     STRINGENT AND COMPLEX REGULATIONS FOR BIOLOGICS IN NORTH AMERICA AND EUROPE
        • 2.1.2.4     HIGH COST AND TECHNICAL REQUIREMENTS TO OBTAIN GMP CERTIFICATIONS
    • 2.2     CELL LINE DEVELOPMENT
    • 2.3     HOST CELL LINES
  • 3     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM
    • 3.1     MICROBIAL EXPRESSION SYSTEMS
    • 3.2     MAMMALIAN EXPRESSION SYSTEM
    • 3.3     OTHERS
  • 4     CELL LINE DEVELOPMENT SERVICES, BY CELL TYPE
    • 4.1     CHO
    • 4.2     MURINE/MOUSE MYELOMA
    • 4.3     BABY HAMSTER KIDNEY (BHK) CELLS
    • 4.4     HYBRIDOMA
    • 4.5     HUMAN EMBRYONIC KIDNEY (HEK) CELLS
    • 4.6     HUMAN EMBRYONIC RETINAL CELLS (PER.C6)
    • 4.7     OTHERS
  • 5     CELL LINE DEVELOPMENT SERVICES, BY APPLICATION
    • 5.1     RESEARCH
    • 5.2     BIOPRODUCTION
    • 5.3     DIAGNOSTICS
  • 6     CELL LINE DEVELOPMENT TECHNOLOGICAL ADVANCEMENTS
  • 7     KEY DEVELOPMENTS
  • 8     MARKET SHARE ANALYSIS
  • 9     COMPANY PROFILES
    • 9.1     ABZENA PLC
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     SERVICE PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     SWOT ANALYSIS
    • 9.2     BOEHRINGER INGELHEIM
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     SERVICE PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     SWOT ANALYSIS
    • 9.3     CATALENT INC.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     SERVICE PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     SWOT ANALYSIS
    • 9.4     CHARLES RIVER LABORATORIES
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     SERVICE PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     SWOT ANALYSIS
    • 9.5     COOK PHARMICA
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     SERVICE PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     SWOT ANALYSIS
    • 9.6     CROWN BIOSCIENCES
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     SERVICE PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     SWOT ANALYSIS
    • 9.7     FUJIFILM HOLDINGS CORPORATION
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     SERVICE PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     SWOT ANALYSIS
    • 9.8     GENSCRIPT BIOTECH CORPORATION
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     SERVICE PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     SWOT ANALYSIS
    • 9.9     HORIZON DISCOVERY GROUP, PLC
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     SERVICE PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     SWOT ANALYSIS
    • 9.1     JHL BIOTECH INC.
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     SERVICE PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     SWOT ANALYSIS
    • 9.11     LONZA GROUP
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     SERVICE PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     SWOT ANALYSIS
    • 9.12     MERCK KGAA
      • 9.12.1     OVERVIEW
      • 9.12.2     FINANCIALS
      • 9.12.3     PRODUCT PORTFOLIO
      • 9.12.4     KEY DEVELOPMENTS
      • 9.12.5     SWOT ANALYSIS
    • 9.13     PATHEON N.V.
      • 9.13.1     OVERVIEW
      • 9.13.2     FINANCIALS
      • 9.13.3     SERVICE PORTFOLIO
      • 9.13.4     KEY DEVELOPMENTS
      • 9.13.5     SWOT ANALYSIS
    • 9.14     RENTSCHLER BIOTECHNOLOGIE GMBH
      • 9.14.1     OVERVIEW
      • 9.14.2     FINANCIALS
      • 9.14.3     SERVICE PORTFOLIO
      • 9.14.4     KEY DEVELOPMENTS
      • 9.14.5     SWOT ANALYSIS
    • 9.15     SARTORIUS STEDIM BIOTECH S.A
      • 9.15.1     OVERVIEW
      • 9.15.2     FINANCIALS
      • 9.15.3     SERVICE PORTFOLIO
      • 9.15.4     KEY DEVELOPMENTS
      • 9.15.5     SWOT ANALYSIS
    • 9.16     SELEXIS SA
      • 9.16.1     OVERVIEW
      • 9.16.2     FINANCIALS
      • 9.16.3     SERVICE PORTFOLIO
      • 9.16.4     KEY DEVELOPMENTS
      • 9.16.5     SWOT ANALYSIS
    • 9.17     SHANGHAI MEDICILON
      • 9.17.1     OVERVIEW
      • 9.17.2     FINANCIALS
      • 9.17.3     SERVICE PORTFOLIO
      • 9.17.4     KEY DEVELOPMENTS
      • 9.17.5     SWOT ANALYSIS
    • 9.18     SHANGPHARMA CORPORATION /SHANGHAI CHEMPARTNER
      • 9.18.1     OVERVIEW
      • 9.18.2     FINANCIALS
      • 9.18.3     SERVICE PORTFOLIO
      • 9.18.4     KEY DEVELOPMENTS
      • 9.18.5     SWOT ANALYSIS
    • 9.19     SYNGENE INTERNATIONAL
      • 9.19.1     OVERVIEW
      • 9.19.2     FINANCIALS
      • 9.19.3     SERVICE PORTFOLIO
      • 9.19.4     KEY DEVELOPMENTS
      • 9.19.5     SWOT ANALYSIS
    • 9.2     WUXI APPTEC
      • 9.20.1     OVERVIEW
      • 9.20.2     FINANCIALS
      • 9.20.3     SERVICE PORTFOLIO
      • 9.20.4     KEY DEVELOPMENTS
      • 9.20.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CELL LINE DEVELOPMENT SERVICES MARKET,BY REGION, (2015-2025) ($MN)
      • TABLE 2     APPROVED BIOLOGICS AND CELL LINE TYPE (2012-2016)
      • TABLE 3     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE, (2012-2016)
      • TABLE 4     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2015-2025) ($MN)
      • TABLE 5     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2015-2025) ($MN)
      • TABLE 6     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • TABLE 7     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2015-2025) ($MN)
      • TABLE 8     CELL LINE DEVELOPMENT TECHNOLOGIES
      • TABLE 9     CELL LINE DEVELOPMENT SERVICES COST
      • TABLE 10     KEY DEVELOPMENTS (2015-2017)
      • TABLE 11     COMPARISON MATRIX OF CELL LINE DEVELOPMENT PLAYERS AND SERVICES OFFERED, (2014-2016) ($MN)
      • TABLE 12     ABZENA PLC: TOTAL REVENUE AND R&D EXPENSES
      • TABLE 13     ABZENA PLC: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 14     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 15     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 16     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 17     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 18     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 19     CATALENT INC: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 20     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 21     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 22     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 23     FUJIFILM HOLDINGS CORPORATION : TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 24     FUJIFILM HOLDINGS CORPORATION : TOTAL REVENUE, BY SEGMENTS (2014-2016) ($MN)
      • TABLE 25     FUJIFILM HOLDINGS CORPORATION : TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 26     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 27     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 28     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 29     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 30     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 31     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 32     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 33     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 34     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 35     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 36     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 37     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 38     PATHEON N.V.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 39     PATHEON N.V.: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 40     SARTORIUS STEDIM: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 41     SARTORIUS STEDIM: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 42     SHANGHAI CHEMPARTNER: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 43     SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 44     SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 45     WUXI APPTEC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MARKET DYNAMICS OF CELL LINE DEVELOPMENT
      • FIGURE 2     CELL LINE DEVELOPMENT SERVICES MARKET,BY REGION, (2016) ($MN)
      • FIGURE 3     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2012-2016)
      • FIGURE 4     CELL LINE DEVELOPMENT SERVICES MARKET,BY EXPRESSION SYSTEM, (2016 V’S 2025) ($MN)
      • FIGURE 5     EXPRESSION SYSTEMS OF SOME APPROVED BIOLOGICS
      • FIGURE 6     CELL LINE DEVELOPMENT SERVICES MARKET,BY CELL TYPE, (2016 VS 2025) ($MN)
      • FIGURE 7     CELL LINE TYPE OF SOME APPROVED BIOLOGICS
      • FIGURE 8     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • FIGURE 9     CELL LINE DEVELOPMENT SERVICES MARKET,BY APPLICATION, (2016 V’S 2025) ($MN)
      • FIGURE 10     KEY DEVELOPMENTS OF CELL LINE DEVELOPMENT MARKET PLAYERS, 2015-2017
      • FIGURE 11     MARKET SHARE ANALYSIS, BY CELL LINE DEVELOPMENT MAJOR PLAYERS (2016)
      • FIGURE 12     OVERVIEW: ABZENA PLC
      • FIGURE 13     SWOT: ABZENA PLC
      • FIGURE 14     OVERVIEW: BOEHRINGER INGELHEIM
      • FIGURE 15     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 16     OVERVIEW: CATALENT INC.
      • FIGURE 17     SWOT: CATALENT INC.
      • FIGURE 18     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 19     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 20     SWOT: COOK PHARMICA
      • FIGURE 21     SWOT: CROWN BIOSCIENCES
      • FIGURE 22     OVERVIEW: FUJIFILM HOLDINGS CORPORATION
      • FIGURE 23     SWOT: FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • FIGURE 24     OVERVIEW: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 25     SWOT: GENSCRIPT BIOSCIENCES CORPORATION
      • FIGURE 26     OVERVIEW: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 27     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 28     SWOT: JHL BIOTECH INC.
      • FIGURE 29     OVERVIEW: LONZA GROUP
      • FIGURE 30     SWOT: LONZA GROUP
      • FIGURE 31     OVERVIEW: MERCK KGAA
      • FIGURE 32     SWOT: MERCK KGAA
      • FIGURE 33     OVERVIEW: PATHEON N.V.
      • FIGURE 34     SWOT: PATHEON N.V.
      • FIGURE 35     SWOT: RENTSCHLER BIOTECHNOLOGIE
      • FIGURE 36     OVERVIEW: SARTORIOUS STEDIUM BIOTECH S.A.
      • FIGURE 37     SWOT: SARTORIUS STEDIUM BIOTECH S.A.
      • FIGURE 38     SWOT: SELEXIS SA
      • FIGURE 39     SWOT: SHANGHAI MEDICILON
      • FIGURE 40     SWOT: SHANGHAI CHEMPARTNER
      • FIGURE 41     OVERVIEW: SYNGENE INTERNATIONAL
      • FIGURE 42     SWOT: SYNGENE INTERNATIONAL
      • FIGURE 43     SWOT: WUXI APPTEC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     AMGEN
      • 2     ABEOMICS
      • 3     ABGENEX
      • 4     ABZENA
      • 5     ABMGOOD
      • 6     ACRO BIOSYSTEMS
      • 7     AMPLYCELL
      • 8     APPLIED STEM CELL
      • 9     ARAGEN (GVK)
      • 10     ATCC
      • 11     ATUM
      • 12     BOEHRINGER INGELHEIM
      • 13     BPS BIOSCIENCE
      • 14     C & M BIOLABS
      • 15     CATALENT
      • 16     CELLOMICS TECHNOLOGY
      • 17     CELONIC
      • 18     CHARLES RIVER LABORATORIES
      • 19     CHROMOS MOLECULAR SYSTEMS
      • 20     COBRA BIOLOGICS
      • 21     COOK PHARMICA
      • 22     CREATIVE BIOLABS
      • 23     CRUCELL
      • 24     CROWN BIOSCIENCE
      • 25     CYTOVANCE BIOLOGICS
      • 26     EUROFINS
      • 27     EVOTEC
      • 28     EXONBIO
      • 29     FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • 30     FUSION ANTIBODIES
      • 31     G&P BIOSCIENCES
      • 32     GEN TARGET
      • 33     GENSCRIPT
      • 34     GLYCOTOPE
      • 35     GOODWINBIOTECHNOLOGY
      • 36     HORIZON DISCOVERY
      • 37     JHL BIOTECH
      • 38     JSR CORPORATION (KBI BIOPHARMA)
      • 39     LAKEPHARMA
      • 40     LFB BIOMANUFACTURING
      • 41     LONZA
      • 42     MABPLEX
      • 43     MERCK KGAA
      • 44     OXFORD GENETICS
      • 45     PATHEON
      • 46     PRECISION ANTIBODY
      • 47     PROBIOGEN
      • 48     PROFACGEN
      • 49     RENTSCHLER BIOTECH
      • 50     SARTORIUS STEDIM BIOTECH S.A.
      • 51     SELEXIS S.A.
      • 52     SGI-DNA
      • 53     SHANGHAI CHEMPARTNER
      • 54     SHANGHAI MEDICILON
      • 55     SINO BIOLOGICAL
      • 56     SPEED BIOSYSTEM
      • 57     SYDLABS
      • 58     SYNGENE
      • 59     TCG LIFESCIENCES
      • 60     TEXCELL
      • 61     TRENZYME
      • 62     UGA BIOPHARMA
      • 63     WUXI APPTEC